Kornimate/medical-research-clean huggingface dataset:
famce-hlp- family-centered obesity management program in primary care settings

Conditions: Childhood Obesity; Family; Behavior, Health; Lifestyle, Healthy

Summary: this clinical trial aims to compare the adiposity and weight status among mother-child dyads with overweight or obesity who receive the fam-ce-hlp intervention with the mother-child dyads with overweight or obesity who did not receive the intervention. the main question\[s\] it aims to answer are: * is there a significant difference in the adiposity and weight status of mother-child dyads with overweight or obesity who received the fam-ce-hlp intervention compared with the mother-child dyads with overweight or obesity who did not receive the intervention? * is there a significant difference in the health behaviors, obesity stage level, and ripple effect of mother-child dyads with overweight or obesity who received the fam-ce-hlp intervention compared with the mother-child dyads with overweight or obesity who did not receive the intervention? participants will be asked to attend a seven-month program comprising two primary therapies: a three-month intensive behavioral therapy (ibt) and a four-month maintenance behavioral therapy (mbt). researchers will compare the intervention group with the treatment-as-usual group (control group) to see if there is a difference in adiposity, weight status, health behaviors, obesity stage level, and ripple effect.


Eligibility criteria:
inclusion criteria: * mother and child dyads with the presence of overweight or obesity (stages 0 to 2) * being omani * mother age 18 years or more * child age 6 to 12 years * mother understand, write, and read in arabic * eligible to receive the health center's services based on their area of residence * has medical clearance to participate in individual exercise sessions * ability to understand study procedures and to comply with them for the entire length of the study. exclusion criteria: * mother or child currently receiving an obesity-related program * mother or child currently on obesity-related procedures * mother or child with a history of obesity-related surgeries in the last 5 years * mother or child is in obesity stage 3 or 4 based on the edmonton obesity staging system * mother who is pregnant during the study time

Keywords: childhood obesity family management primary care
parent-youth teamwork in pediatric asthma management

Conditions: Asthma

Summary: the purpose of this research study is to examine the effectiveness of a parent-youth teamwork treatment and an asthma education treatment in helping children use their asthma medicines correctly. we also want to learn about how these treatments affect parental involvement in asthma care, parent and youth relationships, and children's health care.

noncompliance with medication is a prevalent problem for pediatric asthma patients, particularly for pre-adolescents and adolescents. families reportedly struggle with the transition of expecting adolescents to assume more independence and responsibility in asthma management. parent-child collaborative management of pediatric chronic illness regimens has been related to better adherence to medical regimens and improved health outcome. this study has four aims. the first aim is to investigate the effectiveness of a low-intensity, behavioral intervention aimed at promoting parental involvement in children's asthma management, particularly in improving medication adherence. the second aim is to examine how the role of parental involvement changes across time and participation in a 5-month study. a third aim is to determine whether parent-adolescent conflict is changed by the intervention. the fourth aim is to evaluate whether participation in the treatment program is associated with improved health status (e.g., improved pulmonary function test results). established asthma patients (ages 9-15) will be randomly assigned to one of three groups: treatment intervention (ti), asthma education (ae), and standard care (sc). the ti and ae groups will receive four 30-minute treatment sessions every two weeks. the ti intervention will consist of strategies aimed at promoting parent-youth management in asthma management. the ae group will receive structured reviews of asthma educational materials typically given to asthma patients. sc participants will have no contact with researchers beyond that necessary to gather data. data will be collected from all participants every two weeks for the first 8-weeks of study involvement and also about 3-months after the final treatment session. outcome data will include objective measures of medication adherence, parental involvement in asthma, and health outcome.

Eligibility criteria:
inclusion criteria: * patient has been diagnosed with asthma for at least 6 months * patient can be managed appropriately on study medications as determined by the attending physician exclusion criteria: * patient shows evidence of neurological or significant cognitive impairment

Keywords: pediatric asthma, medication adherence, adolescents
miha-loaded pd-l-silenced dc vaccination after allogeneic sct

Conditions: Hematological Malignancies

Summary: allogeneic stem cell transplantation (allo-sct) is a potent treatment, and sometimes the only curative treatment for aggressive hematological malignancies. the therapeutic efficacy is attributed to the graft-versus-tumor (gvt) response, during which donor-derived cd8+ t cells become activated by recipient minor histocompatibility antigens (miha) presented on dendritic cells (dc). consequently, these alloreactive donor t cells clonally expand, acquire effector functions and kill miha-positive malignant cells. however, in a substantial number of patients persistence and recurrence of malignant disease is observed, indicating that insufficient gvt immunity is induced. this is reflected by our observation that not all patients develop a productive cd8+ t cell response towards miha mismatched between the recipient and donor. we found that the pd-1/pd-l1 co-inhibitory pathway is involved in dampening miha-specific cd8+ t cell expansion and function post-transplantation. therefore, a promising strategy to induce or boost gvt immune responses is pre-emptive or therapeutic vaccination with ex vivo-generated donor dcs loaded with miha that are exclusively expressed by recipient hematopoietic cells and their malignant counterparts. in contrast to pre-emptive donor lymphocyte infusion (dli) with polyclonal donor t cells, this miha-dc vaccination approach has less risk of inducing graft-versus-host disease (gvhd) and the potency to induce more efficient gvt-associated t cell immunity. in addition, the potency of this dc vaccine will be further enhanced by interference with the pd-1/pd-l1 co-inhibitory pathway, using sirna mediated pd-l1/pd-l2 silencing.


Eligibility criteria:
inclusion criteria: * patients with aml, myelodysplasia (mds), all, cml (accelerated or blast phase), cll, mm, malignant nhl or hl, who underwent hla-matched allo-sct * patients positive for hla-a2 and/or hla-b7 * patients positive for ha-1, lrh-1 and/or arhgdib transplanted with corresponding miha-negative donor * patients ≥18 years of age * who performance 0-2 * witnessed written informed consent exclusion criteria: * life expectancy \< 3 months * severe neurological or psychiatric disease * progressive disease needing cytoreductive therapy * hiv positivity * patients with acute gvhd grade 3 or 4 * patients with severe chronic gvhd * patients with active infections (viral, bacterial or fungal) that require specific therapy. acute anti-infectious therapy must have been completed within 14 days prior to study treatment * severe cardiovascular disease (arrhythmias requiring chronic treatment, congestive heart failure or symptomatic ischemic heart disease) * severe pulmonary dysfunction * severe renal dysfunction (serum creatinine \> 3 times normal level) * severe hepatic dysfunction (serum bilirubin or transaminases \> 3 times normal level) * patients with known allergy to shell fish

Keywords: dendritic cells pd-l1/l2 silencing vaccination stem cell transplantation minor histocompatibility antigens
urinary catheter exchange on admission of septic elderly with permanent catheter before initiation of antibiotics

Conditions: Fever; Heart Rate; Blood Pressure; C-Reactive Protein; Erythrocyte Sedimentation Rate

Summary: in the era of emerging antibiotics resistant microbiology, we look for better outcome in the treatment of infections in the elderly. we look for guidelines to manage an elderly who has a permanent urinary catheter, admitting to e.r. with fever/sepsis. we assume that exchanging the permanent urinary catheter prior to the urine culture sample as well as for initiating antibiotic treatment will improve the outcome of the patients.it could help the day-to-day fight for the proper antibiotics treatment to avoid resistance.


Eligibility criteria:
inclusion criteria: * \>65 years * permanent urinary catheter * fever or septic state exclusion criteria: * supra-pubic aspiration catheters * septic shock * i.v. antibiotics initiated before admission
edoxaban treatment in routine clinical practice for patients with non-valvular atrial fibrillation (etna-af-hong kong)

Conditions: Atrial Fibrillation

Summary: in order to understand the risks and benefits of edoxaban use in a real-world clinical setting in the nvaf indication, daiichi-sankyo hong kong proposed this non-interventional study (nis) to gain insight into the safety of edoxaban use in non-preselected patients with nvaf.

edoxaban was approved by the pharmacy and poisons board in hong kong (date: 31 may 2016) for the: prevention of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation (nvaf) with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischemic attack (tia). treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and prevention of recurrent dvt and pe in adults. in order to understand the risks and benefits of edoxaban use in a real-world clinical setting in the nvaf indication, daiichi-sankyo proposed this non-interventional study (nis) to gain insight into the safety of edoxaban use in non-preselected patients with nvaf. real world evidence from routine clinical practice using edoxaban up to 2 years will be collected and evaluated in approximately 200 patients, treated by specialized as well as non-specialized physicians in hospital centers.

Eligibility criteria:
inclusion criteria: * is a nvaf-patient whose physician has made the clinical decision to prescribe edoxaban therapy according to package information * has provided written informed consent to participate in the study exclusion criteria: * is participating in an interventional study

Keywords: real world evidence non-valvular atrial fibrillation observational safety
polysomnography-directed noninvasive ventilation in amyotrophic lateral sclerosis (als)

Conditions: Amyotrophic Lateral Sclerosis (ALS)

Summary: use of noninvasive ventilation (niv, also known colloquially as "bipap") has been associated in some studies with improvement in pulmonary function, quality of life and survival. niv is typically applied during sleep, and without the benefit of sleep study to determine the optimal settings. the investigators have shown that when niv is used in this fashion, failure of nocturnal oxygenation and ventilation is prominent. this study is randomizing patients to standard application of niv vs application guided by use of sleep study data to determine the effect of titrated therapy on pulmonary function, quality of life and survival.


Eligibility criteria:
inclusion criteria: * diagnosis of probable or definite amyotrophic lateral sclerosis (als) per el escorial criteria * between ages of 18 and 80 yrs old exclusion criteria: * inability to clear secretions from the airway * life expectancy \< 6 months from a comorbid condition * dementia sufficient to impair ability to use niv, perform respiratory muscle pressure testing (pfts), or complete health-related quality of life (hrqol) instruments * inability to follow up at the als center on a regular basis * previously diagnosed obstructive sleep apnea

Keywords: amyotrophic lateral sclerosis noninvasive ventilation respiratory dysfunction positive pressure ventilation
tele-clinic visits in pediatric marfan patients using parental echo: the future?

Conditions: Marfan Syndrome

Summary: marfan syndrome (mfs), a connective tissue disorder seen in 1 in 3,000 individuals, causes progressive aortic root dilation that can result in aortic dissection and sudden death. clinical care focuses on monitoring the aortic root by serial echocardiography (echo) to guide medical treatment and elective aortic root surgery in a specialized clinic every 6-12 months. this monitoring protocol, coupled with surgical intervention, has doubled the median life expectancy which was previously only 32 years. however, this surveillance carries significant health care costs at \>$50 million dollars/year on echos alone (at $3-4k each) in children and adolescents in the us, as well as substantial burden on families residing far from specialized centers. a clinic visit delivered to mfs patients via live-video conferencing at home (tele-visit) could shift this paradigm, if a home echo could be obtained. here, the investigator will train parents of pediatric marfan patients to take echo images using a hand held device, height, weight, blood pressure, medical history, and listen to the heart of their child. then, the investigators will ask them to take the equipment home and collect the same data at home during a tele-clinic visit, with further instruction by the study team through secure live-video conferencing.

in the proposed intervention, every patient (n=60) will have a tele-visit and an on-site clinic visit 1 day apart. parents will have a 1-hour hands-on training session to acquire basic echo images on their children with the same hand-held device that will be used during the tele-visit. tele-visit elements will include interim medical history by the parent and patient, and weight, height, vital signs, digital cardiac auscultation, and home echo (transferred via internet for remote interpretation), all obtained by the parent. two mfs physicians, following our routine mfs care protocol, will administer either the tele-visit or on-site clinic visit, masked to the findings of the other. two independent echo readers will analyze home and clinic echos to measure reproducibility.

Eligibility criteria:
inclusion criteria: * 5-19 years of age (patient) * seen in at least 2 prior clinic visits * marfan syndrome by revised ghent criteria * presence of parent at home exclusion criteria: * prior aortic surgery * known cardiomyopathy * known arrhythmia * aortic root \> 4.5 cm in prior clinic visit * pregnancy
sperm dna damage in β-thalassemia major: is there a role for antioxidants?

Conditions: Endocrine Disease; Fertility Decreased Male; DNA Damage

Summary: accumulation of iron in patients with beta thalassemia major causes free radical formation which leads to damage of biological membranes. sperm dna damage may result from these generated antioxidants. we aimed at investigating the current dna damage in the sperms of adult patients with beta thalassemia major and the effect generated by giving antioxidant treatment for 6 months.


Eligibility criteria:
inclusion criteria: * pubertal patients with beta thalassemia major exclusion criteria: * associated endcrinopathy
a clinical performance of two soft toric contact lenses

Conditions: Astigmatism

Summary: the study objective was to gather short-term clinical performance data for two soft toric contact lenses.

this participant-masked, non-randomized, controlled non-dispensing study was to compare the performance of two soft toric lenses. participants attended one study visit which lasted for approximately 1.5 hours.

Eligibility criteria:
inclusion criteria: * they are of legal age (18) and capacity to volunteer. * they understand their rights as a research subject and are willing and able to sign a statement of informed consent. * they are willing and able to follow the protocol. * they currently wear soft contact lenses, or have done so within the past two years. * they have ocular astigmatism in both eyes of between 0.75dc and 3.00dc. * they are expected to be able to be fitted with the study lenses within the power range available. exclusion criteria: * they have an ocular disorder which would normally contra-indicate contact lens wear. * they have a systemic disorder which would normally contra-indicate contact lens wear. * they are using any topical medication such as eye drops or ointment. * they are aphakic. * they have had corneal refractive surgery. * they have any corneal distortion resulting from previous hard or rigid lens wear or have keratoconus. * they are pregnant or lactating. * they have an eye or health condition including an immunosuppressive or infectious disease which would, in the opinion of the investigator, contraindicate contact lens wear or pose a risk to study personnel; or a history of anaphylaxis or severe allergic reaction. * they have taken part in any contact lens or care system clinical research within two weeks prior to starting this study.
the use of simulated patients during basic-first aid courses for laypeople

Conditions: Burns; Stroke

Summary: background: teaching first aid to laypeople is a cost-effective way to improve public health. however, it is currently unclear what the most effective ways are to teach first aid. it has already been shown that simulated patients have an added value in teaching emergency care to healthcare professionals. this paper describes the protocol for a cluster-randomized controlled trial that will investigate the influence of using a simulated patient during basic first aid training for laypeople on laypeople's knowledge, skills and self-efficacy. hypothesis: the null hypothesis of this research is that the use of simulated patients during basic first aid training does not result in a statistically significant change in knowledge, skills and self-efficacy concerning the first aid topics for which a simulated patient is used. the alternative is that knowledge, skills and self-efficacy will be influenced by using simulated patients. methods: this study will be a cluster-randomized controlled trial, that will take place from september 2018 to june 2020. the study population will consist of employees taking a three day first aid certification course with the belgian red cross. the employers requesting a first aid course will be randomised in receiving a course with or without simulated patient. the simulated patient will only be used for the topics first aid for burns and first aid for stroke in the intervention group. the participants will complete a questionnaire to measure their knowledge and self-efficacy before and after the course, and complete a practical skills test after the course testing these first aid topics. to test whether the retention of first aid knowledge and self-efficacy is influenced by using a simulated patient during a certification course, participants following a refresher course one year after the certification course will complete a follow-up questionnaire. this cluster-randomized controlled trial will be, to the investigator's knowledge, the first to investigate the added value of simulated patients during first aid courses for laypeople.


Eligibility criteria:
inclusion criteria: * employed in a company requesting a basic first aid course taught by the belgian red cross exclusion criteria: * employed in a company that purposefully requests a simulated patient * employed in a company that requests a course in a language other than dutch (french, english) * participants \< 16 years of age

Keywords: first aid simulated patient laypeople
fluorine-18-α-methyltyrosine positron emission tomography for diagnosis and staging of lung cancer

Conditions: Carcinoma, Non-Small-Cell Lung

Summary: objective: l-\[3-18f\]-α-methyltyrosine (fmt) is an amino-acid tracer for pet. we evaluated the diagnostic usefulness of 18f-fmt pet in non-small cell lung cancer (nsclc) patients. tumor uptake of 18f-fmt pet was compared with 18f-fdg pet and the correlation with l-type amino acid transporter 1 (lat1) expression also investigated. method: fifty patients with nsclc were enrolled in this study, and a pair of pet study with 18f-fmt and 18f-fdg was performed. lat1 expression and ki-67 labeling index of the resected tumors were analyzed by immunohistochemical study.


Eligibility criteria:
inclusion criteria: * proven or suspected non-small cell lung cancer exclusion criteria: * uncontrolled diabetes mellitus

Keywords: fluorine-18-α-methyltyrosine, positron emission tomography, fluorodeoxyglucose lung cancer, amino acid transportor 1, ki-67 proven or suspected non-small cell lung cancer were enrolled in the study
comparative study of the effects of dry needling and botulinum toxin type a as a treatment for lower limb post-stroke spasticity

Conditions: Stroke

Summary: this is a randomized parallel group clinical trial which will be conducted in three countries (spain, canada and belgium) comparing botulinum toxin type a (btx-a) and dry needling (dn) effectiveness for post-stroke spasticity in participants who had a first stroke in the previous 12 months and have plantar flexor spasticity. participants will be randomly allocated to receive either one session of btx-a or 12 weekly sessions of dn. blinded evaluators will assess the effects before, during, and after treatment, and at a 4-week follow-up.

the primary hypothesis is that the effects of dn on post-stroke spasticity in the lower limbs at the spinal level is comparable to btx-a in reducing spasticity by decreasing stretch reflex excitability. sample size: spain, canada and belgium will recruit 90 participants (30 per country) the platform used for randomization and electronic data collection will be research electronic data capture (redcap): https://www.project-redcap.org/. a shared license will be used among the countries involved in the study. data dictionary: * dn: dry needling * btx-a: botulinum toxin type a * tsrt: tonic stretch reflex threshold * mas: modified ashworth scale * 10mwt: 10 metre walk test * tug: timed up \& go * ppi: public and patient involvement * sop: standard operating procedure

Eligibility criteria:
inclusion criteria: 1. aged 18-75 years. 2. post-stroke spasticity in ankle plantar flexors (modified ashworth scale (mas) scores of 1-2). 3. first stroke. 4. 0-12 months evolution. 5. no previous btx-a or dn treatment for spasticity. 6. ankle passive range of motion ≥ 20° (approximately) with knee flexion \~30°. 7. independent ambulation with or without aids. exclusion criteria: 1. medical conditions interfering with data interpretation. 2. contraindications for btx-a or dn treatment. 3. changes in anti-spasticity medication dosage (if appropriate), either during the trial or within the 3 months prior to participation. 4. pregnant or breastfeeding.

Keywords: stroke [mesh] dry needling muscle spasticity [mesh] botulinum toxins [mesh] tonic stretch reflex threshold ultrasound imaging gait analysis quality of life [mesh]